Korea AstraZeneca's decision to withdraw 슬롯사이트 추천 raises industry concerns over market fluctuations.
Plans for supply disruption of AstraZeneca's diabetes treatment, 슬롯사이트 추천, featuring the SGLT2 inhibitor Dapagliflozin, have sparked scrutiny and industry attention.This move, disclosed during a Korea AstraZeneca town hall on December 8th, is attributed to ongoing litigation regarding price reduction and heightened competition in the diabetes treatment sector. The potential withdrawal of 슬롯사이트 추천, a significant revenue generator with .9 million in over-the-counter prescription sales, could prompt notable shifts in the market landscape.
슬롯사이트 추천, a blockbuster product registering .7 million in sales last year, faced patent expiration on April 7th, leading to the introduction of numerous generic versions by various Korean pharmaceutical companies. The prevalence of Dapagliflozin-containing products from these companies has become ubiquitous in the market.
Furthermore, 슬롯사이트 추천 encountered a price reduction, dropping from >510_word_end<.56 to >510_word_end<.39 following the introduction of generics. However, legal intervention via a lawsuit halted this decrease, maintaining the price at >510_word_end<.56.
Legal battles have ensnared 슬롯사이트 추천's fate, with arguments highlighting its distinct clinical value for chronic heart failure and kidney disease, beyond its use solely as a diabetes treatment. Despite efforts to expand reimbursement criteria, the reception towards AstraZeneca remains unfavorable, hampering the inclusion of chronic heart failure and kidney disease treatment under prevailing circumstances.
Nevertheless, combination medications involving 슬롯사이트 추천 are expected to persist. Collaborations such as 'Sidapvia' with SK Chemical and Il Dong Pharmaceutical's 'Qtern' are projected to continue their sales in the Korean market.
Should 슬롯사이트 추천 proceed with withdrawal, the diabetes treatment sector is anticipated to experience notable fluctuations. Daewoong Pharmaceutical's Envlo and Boehringer Ingelheim's 'Jardiance' are poised to benefit from the potential exit of 슬롯사이트 추천, alongside increased competition from generics and DPP4 inhibitor-based diabetes medications.
A pharmaceutical industry insider noted that while Korea AstraZeneca revealed plans for 슬롯사이트 추천's product approval cancellation, the timing remains uncertain due to intricate issues. They emphasized the rarity of withdrawing a major product and suggested impending upheaval in the diabetes market.